Medical Affairs in Rare Disease and Gene Therapy - Why a different approach?

In today's episode of the MAPS "Elevate" podcast, we'll be looking at considerations for Medical Affairs in Rare Disease and Gene Therapy and reviewing the following questions:How do you the see the role of Medical Affairs evolving in the era of advance therapeutics like gene therapy, often investigated for rare disorders? Are there specialized skillsets MA professionals need to be successful in this area? What are three major differences in approach to Med Affairs planning in rare disease, whether or not there is a gene therapy involved? From your experience, what are the biggest hurdles for Med Affairs professionals educating HCPs on gene therapy? It sounds really exciting in concept, but does the reality differ in practice? What advice is there for Med Affairs colleagues wanting to work in either rare disease or gene therapy? Are there specialized roles coming up in this space, different from current roles?